

## 1 **Supplementary information**

### 2 **Supplemental Methods**

3 **Measurement of anti-SARS-CoV antibody ELISA titers.** Whole blood and BALF were  
4 collected from SAR-CoV-infected mice at 6 days p.i. and sera were prepared. ELISA titers were  
5 measured as follows. 96-well Maxisorp Immuno Plates (Nunc) were coated with  $2 \times 10^5$  PFU of  
6 formaldehyde and UV-inactivated SARS-CoV (BEI Resources). After washing, wells were  
7 exposed for 1.5 hours to serially diluted sera or BALF from naïve or infected mice. Wells were  
8 washed and then treated sequentially with 1:2000 dilution of HRP-conjugated goat anti-mouse  
9 IgG/IgM/IgA secondary antibody (Pierce Biotechnology) for 1 hour at 37 °C and  
10 tetramethylbenzidine (K-Blue MAX TMB substrate, Neogen Corporation) for 10 minutes at  
11 room temperature. Reactions were stopped with 1.5 M H<sub>2</sub>SO<sub>4</sub>, and absorbance was read at 450  
12 nm. The total anti-SARS-CoV IgG/IgM/IgA ELISA titer was defined as the highest dilution of  
13 the test sample giving a twofold increase over the naïve mice samples.


14

15 **Measurement of hemagglutination inhibition (HAI) titers in sera and BALF.** Whole blood  
16 and BALF were collected from IAV-infected mice at 21 days p.i. and sera were prepared. To  
17 measure HAI titers, serum and BALF samples were serially diluted two-fold from 1:5 to 1:320,  
18 mixed with 4 HA units of IAV for 30 minutes at room temperature, and then incubated with a  
19 1% suspension of chicken red blood cells for 45 minutes at room temperature to visualize the  
20 reactions.

21


# Supplemental Figures

## Supplemental Figure 1




**Supplemental Figure 1. Similar antigen uptake, processing and presentation by rDCs from young and aged mice.** (A) 6-week-old and 22-month-old mice were treated with 10  $\mu\text{g}/75 \mu\text{l}$  OVA-FITC or OVA-DQ i.n. After 1h, lungs were harvested and single cell suspensions prepared. The fluorescence intensities of OVA-FITC or OVA-DQ associated with  $\text{CD11c}^+\text{MHCII}^+\text{CD11b}^+$  and  $\text{CD11c}^+\text{MHCII}^+\text{CD103}^+$  rDCs are shown. (B) 6-week-old and 22-month-old mice were inoculated with 200  $\mu\text{g}/75 \mu\text{l}$  OVA-FITC or OVA-DQ i.n.. After 18 hours, single cell suspensions were prepared from lung DLNs. The percentage of OVA-FITC<sup>+</sup> or OVA-DQ<sup>+</sup> cells within the  $\text{CD11c}^+\text{MHCII}^+$  DC population is shown. 5-6 mice/group/experiment; data are representative of 3 independent experiments. (C) OVA-FITC<sup>+</sup> migratory rDCs were sorted from lung DLNs of 6-week-old and 22-month-old mice using a FACSDiva 18 hours after i.n. OVA-FITC treatment. OT-I CD8 T cells were negatively enriched from the spleens of naïve OT-I Tg mice and stained with 2.5  $\mu\text{M}$  CFSE.  $1 \times 10^4$  OVA-FITC<sup>+</sup> rDCs and  $1 \times 10^5$  OT-I CD8 T cells were cultured in a volume of 200  $\mu\text{l}$  in round-bottomed 96-well plates (Corning) at 37 °C for 4 days in complete RPMI 1640 media. CD8 T cells were analyzed for CFSE dilution by flow cytometry. Data are representative of 3 independent experiments.

## Supplemental Figure 2



**Supplemental Figure 2. Defective SARS-CoV-specific CD8 T cell response in aged mice is not T cell-intrinsic.** (A)  $5 \times 10^7$  splenocytes from 6-week-old or 12-month-old (B6-Thy1.2) donor mice were adoptively transferred into 6-week-old B6 (B6-Thy1.1) recipients prior to SARS-CoV infection. (B)  $5 \times 10^7$  splenocytes from 6-week-old (B6-Thy1.1) mice were adoptively transferred into 6-week-old or 12-month-old (B6-Thy1.2) recipient mice prior to SARS-CoV infection. Flow cytometric analysis of endogenous and exogenous epitope S436-specific CD8<sup>+</sup> T cell responses assessed by intracellular IFN- $\gamma$  staining at day 6 p.i. is shown. Numbers represent the percentage of IFN- $\gamma$ <sup>+</sup> CD8 T cells. 4 mice/group/experiment. Data are representative of 2 independent experiments.


## Supplemental Figure 3




**Supplemental Figure 3. Treatment with PGD<sub>2</sub> antagonist BW A868C enhances rDC migration and T cell responses in SARS-CoV-infected 22 month old mice.** (A) 22-month-old mice were i.n. inoculated with 50  $\mu$ l 8 mM CFSE. Six hours after instillation, mice were infected with SARS-CoV together with BW A868C or vehicle. After 18 hours, single cell suspensions were prepared from lung DLNs. The numbers represent the percentage of CFSE<sup>+</sup> cells within the CD11c<sup>+</sup>MHCII<sup>+</sup> DC population per LN. Total CFSE<sup>+</sup> DC numbers per LN are also shown. (B) Lung cells were harvested from and 22-month-old B6 mice 6 days after SARS-CoV infection. Tetramer staining for epitope S436, and total numbers of CD8 T cells and tetramer S436<sup>+</sup> CD8 T cells are shown. Numbers represent the percentage of tetramer<sup>+</sup> CD8 T cells. n=3-4 mice/group/experiment. Data are representative of 3 independent experiments. (C) 22-month-old mice were i.n. infected with  $1 \times 10^4$  PFU MA15 virus. Mortality was monitored daily. n= 8 mice in vehicle group; 10 mice in BW A868C group. *P* value, determined by a Kaplan-Meier survival test, is: *P* = 0.017.

## Supplemental Figure 4

### A: SARS-CoV



### B: IAV



**Supplemental Figure 4. Treatment with PGD<sub>2</sub> antagonist BW A868C does not enhance antibody responses in SARS-CoV and IAV-infected old mice.** (A) Sera and BALF from SARS-CoV-infected mice at 6 days p.i. were analyzed for total IgG/IgM/IgA by ELISA as described in Supplemental Materials and Methods. The ELISA titer was defined as the highest dilution of the test sample giving a twofold increase over the naïve mice samples. n=4 mice/group. (B) Sera and BALF from IAV-infected mice at 21 days p.i. were serially diluted two-fold from 1:5 to 1:320, mixed with 4 HA units of IAV, and then incubated with a 1% suspension of chicken red blood cells for 45 minutes at room temperature to visualize HAI titers. n=3-5 mice/group.